Byondis B.V.
Byondis is a Dutch biopharmaceutical company dedicated to transforming cancer treatment through innovative targeted medicines, including antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). The company focuses on research, development, and manufacturing of next-generation therapies to address unmet medical needs in cancer and autoimmune diseases. With fully integrated in-house R&D and GMP manufacturing facilities, Byondis aims to deliver transformative therapies efficiently and safely.
Industries
Nr. of Employees
large (251-1000)
Byondis B.V.
Microweg 22, 6545 CM Nijmegen, The Netherlands
Patents
Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
US-12178881-B2
View DetailsSite-specific conjugation of linker drugs to antibodies and resulting ADCs
US-12180552-B2
View Details
Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
US-12178881-B2
View DetailsSite-specific conjugation of linker drugs to antibodies and resulting ADCs
US-12180552-B2
View DetailsProducts
Clinical‑stage SIRPα‑targeting monoclonal antibody (Phase I)
A SIRPα‑directed monoclonal antibody program designed to block the CD47‑SIRPα myeloid immune checkpoint to potentiate antibody-mediated tumor cell clearance; developed with preclinical characterization and entering first‑in‑human dose-escalation and expansion studies.
Clinical‑stage CD123‑targeting antibody‑drug conjugate (Phase I)
An ADC program targeting CD123 (IL‑3Rα) for hematologic malignancies, using cleavable duocarmycin‑based linker‑drug chemistry and site‑specific conjugation technologies to induce tumor cell apoptosis and enable combination with standard-of-care agents.
Duocarmycin-based cleavable linker-drug platform
A next‑generation cleavable linker‑drug platform using duocarmycin-based payloads engineered for high circulation stability and tumor-selective activation to widen the therapeutic index for ADCs.
Conjugation platform suite (site‑specific, native‑disulfide, dual‑payload)
Collection of antibody conjugation technologies enabling site-specific cysteine conjugation, partially reduced native disulfide conjugation, branched linkers and dual-payload constructs to produce well-defined ADCs with optimized manufacturability and therapeutic index.
Clinical‑stage SIRPα‑targeting monoclonal antibody (Phase I)
A SIRPα‑directed monoclonal antibody program designed to block the CD47‑SIRPα myeloid immune checkpoint to potentiate antibody-mediated tumor cell clearance; developed with preclinical characterization and entering first‑in‑human dose-escalation and expansion studies.
Clinical‑stage CD123‑targeting antibody‑drug conjugate (Phase I)
An ADC program targeting CD123 (IL‑3Rα) for hematologic malignancies, using cleavable duocarmycin‑based linker‑drug chemistry and site‑specific conjugation technologies to induce tumor cell apoptosis and enable combination with standard-of-care agents.
Duocarmycin-based cleavable linker-drug platform
A next‑generation cleavable linker‑drug platform using duocarmycin-based payloads engineered for high circulation stability and tumor-selective activation to widen the therapeutic index for ADCs.
Conjugation platform suite (site‑specific, native‑disulfide, dual‑payload)
Collection of antibody conjugation technologies enabling site-specific cysteine conjugation, partially reduced native disulfide conjugation, branched linkers and dual-payload constructs to produce well-defined ADCs with optimized manufacturability and therapeutic index.
Services
Onsite GMP production of monoclonal antibodies and antibody-drug conjugates, including clinical batch manufacture, QC testing and release.
Conjugation services for high‑potency payloads in controlled clean rooms, process development for conjugation platforms and in‑process controls.
End-to-end research capabilities including target identification, lead finding, preclinical efficacy and safety testing, biomarker identification, and clinical program design.
Analytical services including higher-order structure assessment, mass-spectrometry based characterization, and potency/assay development to support development and release.
Structuring of platform access agreements, license and supply agreements, and regional commercialization collaborations.
Onsite GMP production of monoclonal antibodies and antibody-drug conjugates, including clinical batch manufacture, QC testing and release.
Conjugation services for high‑potency payloads in controlled clean rooms, process development for conjugation platforms and in‑process controls.
End-to-end research capabilities including target identification, lead finding, preclinical efficacy and safety testing, biomarker identification, and clinical program design.
Analytical services including higher-order structure assessment, mass-spectrometry based characterization, and potency/assay development to support development and release.
Structuring of platform access agreements, license and supply agreements, and regional commercialization collaborations.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Monoclonal antibody discovery and development
- Preclinical pharmacology and translational research
- Clinical trial design and execution (Phase I–III)
Key Technologies
- Cleavable duocarmycin-based linker-drug chemistry
- Site-specific cysteine conjugation
- Native disulfide partial-reduction conjugation
- Branched linker and dual‑payload architectures
News & Updates
Byondis and Glycotope have entered into a platform access agreement to discover and develop antibodies targeting tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets). The collaboration aims to leverage Glycotope's technology platform to generate highly tumor-specific monoclonal antibodies for various modes of action, including ADCs and cellular therapies.
Marieke van Gent has been appointed as the new vice president of Intellectual Property at Byondis. She is a European patent attorney with over 25 years of experience in IP, having worked in leadership roles in biotech, pharma, and chemicals. She will be responsible for creating and executing IP strategies to support Byondis' objectives.
Michel Eppink, Senior Director Downstream Processing at Byondis, will present on Cell Tolerant Radial Affinity Chromatography (cTRAC) as a capture step for monoclonal antibodies at the ECB2024. The presentation will discuss process improvements through integration of upstream and downstream processes.
Byondis and medac have entered into agreements to commercialize SYD985, an anti-HER2 antibody-drug conjugate, pending regulatory approval. The collaboration aims to bring this therapy to patients with HER2-expressing cancers, including breast and endometrial cancer.
Encouraging preclinical data on BYON4228, an anti-SIRPα monoclonal antibody targeting the CD47-SIRPα axis, was published. The antibody potentiates destruction of tumor cells and is scheduled to enter Phase I clinical trials.
A Phase III trial evaluating the efficacy of SYD985 in HER2-positive breast cancer.
Byondis and Glycotope have entered into a platform access agreement to discover and develop antibodies targeting tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets). The collaboration aims to leverage Glycotope's technology platform to generate highly tumor-specific monoclonal antibodies for various modes of action, including ADCs and cellular therapies.
Marieke van Gent has been appointed as the new vice president of Intellectual Property at Byondis. She is a European patent attorney with over 25 years of experience in IP, having worked in leadership roles in biotech, pharma, and chemicals. She will be responsible for creating and executing IP strategies to support Byondis' objectives.
Michel Eppink, Senior Director Downstream Processing at Byondis, will present on Cell Tolerant Radial Affinity Chromatography (cTRAC) as a capture step for monoclonal antibodies at the ECB2024. The presentation will discuss process improvements through integration of upstream and downstream processes.
Byondis and medac have entered into agreements to commercialize SYD985, an anti-HER2 antibody-drug conjugate, pending regulatory approval. The collaboration aims to bring this therapy to patients with HER2-expressing cancers, including breast and endometrial cancer.
Encouraging preclinical data on BYON4228, an anti-SIRPα monoclonal antibody targeting the CD47-SIRPα axis, was published. The antibody potentiates destruction of tumor cells and is scheduled to enter Phase I clinical trials.
A Phase III trial evaluating the efficacy of SYD985 in HER2-positive breast cancer.